Couple With Cancer Wins $2 Billion in Case Against Monsanto

In determining that the illnesses came about from exposure to glyphosate in Roundup, a California jury delivers the biggest loss so far to the herbicide manufacturer in lawsuits about the product.

Written byCatherine Offord
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, NODEROG

Update (July 26): As several legal experts predicted, the $2 billion award for the couple was reduced yesterday to a smaller amount, $86.7 million, after a judge presiding over the case found the punitive portion of the damages to be excessive and unconstitutional. The plaintiffs have yet to formally accept the award, which now consists of around $17 million in compensatory and $69 million in punitive damages, Reuters reports. Bayer has said in a statement that it will appeal for the punitive damages to be struck completely.

A jury in California has ordered global agribusiness Monsanto to pay more than $2 billion to a couple who developed non-Hodgkin’s lymphoma after years of using the company’s weedkiller, Roundup. The verdict—which mandates a payment of $2 billion in punitive damages and a further $55 million in compensatory damages—was delivered on Monday (May 13) and marks the third and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies